In 2023, Pan et al. reported a phase I clinical trial (NCT05032599) in which donor-derived CD5-KO CD5-redirected CAR-T cell therapy was effective for CD7-negative relapsed T-ALL after CD7 CAR-T cell treatment. Here, CD5 is linked to acute lymphoblastic leukemia.